These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30 related articles for article (PubMed ID: 2446827)
1. Use of monoclonal antibodies as probes for oncogene products. Niman HL Immunol Ser; 1990; 53():189-204. PubMed ID: 2100555 [No Abstract] [Full Text] [Related]
2. Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A. Yu D; Shi D; Scanlon M; Hung MC Cancer Res; 1993 Dec; 53(23):5784-90. PubMed ID: 7902209 [TBL] [Abstract][Full Text] [Related]
3. [Proteins and tumor growth]. Shapot VS Vestn Akad Med Nauk SSSR; 1982; (3):22-9. PubMed ID: 6178231 [No Abstract] [Full Text] [Related]
4. Changes in heparan sulfate pattern but not in oncogene expression correlate with tumor growth in spontaneous transformation of cells. Smith CA; Winterbourne DJ; McFarland VW; Mora PT Oncogene Res; 1987; 1(4):325-41. PubMed ID: 2966923 [TBL] [Abstract][Full Text] [Related]
5. Modulation of the c-myb, c-myc and p53 mRNA and protein levels during induced murine erythroleukemia cell differentiation. Richon VM; Ramsay RG; Rifkind RA; Marks PA Oncogene; 1989 Feb; 4(2):165-73. PubMed ID: 2648254 [TBL] [Abstract][Full Text] [Related]
6. Photodynamic therapy resistant human colon carcinoma HT29 cells show cross-resistance to UVA but not UVC light. Zacal N; Rainbow AJ Photochem Photobiol; 2007; 83(3):730-7. PubMed ID: 17576382 [TBL] [Abstract][Full Text] [Related]
7. The ras gene family. Lowy DR; Willumsen BM Cancer Surv; 1986; 5(2):275-89. PubMed ID: 3096566 [TBL] [Abstract][Full Text] [Related]
8. High frequency of mas oncogene activation detected in the NIH3T3 tumorigenicity assay. van 't Veer LJ; van den Berg-Bakker LA; Hermens RP; Deprez RL; Schrier PI Oncogene Res; 1988; 3(3):247-54. PubMed ID: 3060802 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies. Kurokawa M; Tanaka T; Tanaka K; Ogawa S; Mitani K; Yazaki Y; Hirai H Oncogene; 1996 Feb; 12(4):883-92. PubMed ID: 8632911 [TBL] [Abstract][Full Text] [Related]
10. Biological and molecular analysis of p53 cellular-encoded tumor antigen. Rotter V; Wolf D Adv Cancer Res; 1985; 43():113-41. PubMed ID: 3887856 [No Abstract] [Full Text] [Related]
12. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein. Weiner DB; Kokai Y; Wada T; Cohen JA; Williams WV; Greene MI Oncogene; 1989 Oct; 4(10):1175-83. PubMed ID: 2571965 [TBL] [Abstract][Full Text] [Related]
13. Transformation of follicular lymphoma. Expression of p53 and bcl-2 oncoprotein, apoptosis and cell proliferation. Symmans WF; Katz RL; Ordoñez NG; Dalton H; Romaguera JE; Cabanillas F Acta Cytol; 1995; 39(4):673-82. PubMed ID: 7631541 [TBL] [Abstract][Full Text] [Related]
14. Analysis of human p53 proteins and mRNA levels in normal and transformed cells. Matlashewski G; Banks L; Pim D; Crawford L Eur J Biochem; 1986 Feb; 154(3):665-72. PubMed ID: 2419131 [TBL] [Abstract][Full Text] [Related]
15. [Modified oncoprotein p53 in the human tumor cell line HT 1080]. Maĭmets TO; Jenkins JR Dokl Akad Nauk SSSR; 1987; 296(3):757-9. PubMed ID: 2446827 [No Abstract] [Full Text] [Related]
16. High prevalence of bcl-2 oncoprotein expression in small cell lung cancer. Higashiyama M; Doi O; Kodama K; Yokouchi H; Tateishi R Anticancer Res; 1995; 15(2):503-5. PubMed ID: 7763030 [TBL] [Abstract][Full Text] [Related]
17. Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Kim CY; Tsai MH; Osmanian C; Graeber TG; Lee JE; Giffard RG; DiPaolo JA; Peehl DM; Giaccia AJ Cancer Res; 1997 Oct; 57(19):4200-4. PubMed ID: 9331075 [TBL] [Abstract][Full Text] [Related]